About
Lutz Frölich is psychiatrist, psychotherapist and a clinical neuroscientist, active in the field of dementia research and care. He is professor of Old Age Psychiatry at the University of Heidelberg and heads the Department of Geriatric Psychiatry at the Central Institute of Mental Health in Mannheim. His department provides fully sectorized hospital care for the elderly Mannheim citizens, with outpatient services to nursing homes and a large memory clinic. His research interests are in the area of biomarker and therapy research in Alzheimer's disease and related dementias, including expertise in clinical trials. He is Co-Founder (2002) and Co-Chair (since 2010) of the European Alzheimer Disease Consortium, Executive Board member of the German Dementia Competence Network, and a Working group leader of the German Network of Memory Clinics as well as a fellow of the Network on Aging Research at Heidelberg University. He has been Co-Founder and Executive Board member of three regional German Alzheimer Societies (Würzburg, Frankfurt, Mannheim). His scientific output includes >400 scientific papers and >50 textbook articles.
Disclosures Lutz Frölich: 2020 – 2023
Dr Frölich is a Full Professor at the University of Heidelberg, Germany. He holds no patents, stocks or shares.
German governmental funding (BMBF, G-BA) (CBTlate, ENABLE), EU-Horizon2020 funding (RECAGE, EADB, RADAR-AD, 2D-BioPAD) and Charity organizations (FRAILBRAIN)
Consulting/advisory activities: Biogen, Eisai, Grifols, Neurimmune, Noselab, NovoNordisk, Roche, Schwabe, TauRX
Endpoint or Safety Committees: Avanir/Otsuka, Pharmatrophix, Forschungszentrum Jülich, Charité Berlin, Neurimmune, Neurokine Therapeutics LLC, NSC Therapeutics, reMYND N.V, Vivoryon
Clinical trial investigator activities: Anavex, Alector, Boehringer Ingelheim, Eisai Inc., Functional Neuromodulation, Hummingbird, Immungenetics, Neurimmune, Noselab, Novo Nordisk